| Name | GSK-3β inhibitor 3 |
| Description | GSK-3β inhibitor 3 is a potent, selective, and irreversible covalent inhibitor of glycogen synthase kinase 3β (GSK-3β) with an IC50 of 6.6 μM, and can be used to study acute promyelocytic leukemia. |
| In vitro | GSK-3β inhibitor 3 (compound 4-3) (6.25-100 μM; 24-48 h) dose-dependently inhibits cell viability, with IC50s of 19.56 μM and 26.42 μM in NB4 and NB4-R1 cells at 24 h, respectively. It (12.5-100 μM; 24 h) also significantly increases apoptosis in a dose-dependent manner in NB4 and NB4-R1 cells. Additionally, GSK-3β inhibitor 3 (100 μM) inhibits GSK-3α activity by 87.3%.[1] |
| In vivo | GSK-3β inhibitor 3 (compound 4-3) (15 mg/kg; a single i.p.; Balb/c female nude mice) demonstrates a T1/2 of 14.2 hours, an AUClast of 3503.42 ng/mL•h, and a Cmax of 515 ng/mL in mice.[1] Additionally, GSK-3β inhibitor 3 (15 mg/kg/d; i.p. for 2 weeks; Balb/c female nude mice) inhibits tumor growth by 75.97% compared to the vehicle control.[1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 225 mg/mL (687.3 mM), Sonication is recommended.
|
| Keywords | GSK-3β inhibitor 3 | GSK3β inhibitor 3 | GSK-3β | GSK-3beta inhibitor 3 | GSK-3b inhibitor 3 | GSK3 | GSK 3β inhibitor 3 | Apoptosis |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Ethyl linoleate | Formamide | Dimethyl phthalate | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | Glycolysis Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | HIF-1 Signaling Pathway Compound Library | Kinase Inhibitor Library | Anti-Obesity Compound Library | Inhibitor Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Cancer Compound Library |
United States
